C5AR1 and hepatocellular carcinoma: Taken together, our studies reveal a novel mechanism that LukS-PV targeting C5aR1 inhibits HCC cell proliferation by the HDAC7-Wnt/β-catenin axis, suggesting that LukS-PV may have potential as a therapeutic drug for HCC treatment.